Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an "autopilot" rather than a "digital copilot" risks a dangerous "deskilling" ...

ChemR23 agonism targets inflammatory and neurosensory biology, with receptor expression on ocular immune cells and dorsal root ganglion neurons/glia supporting a mechanistic rationale for NCP symptom ...

Commercial rollout includes direct purchasing and specialty distribution, alongside scaled investments in awareness, education, screening, and diagnosis to drive earlier keratoconus detection. Epioxa ...

NovaBridge Biosciences and Visara have announced topline results from their phase 2a study of VIS-101 for retinal vascular ...

Physiologic AL varies materially with age, sex, height, and ethnicity, undermining fixed AL thresholds as broadly applicable risk stratifiers in typical pediatric myopia. Retinal pathology risk ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...

Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

Enrollment spans Europe, the US, and Canada, targeting ~324 GA patients in a randomized, double-masked, sham-controlled phase 2 program. Dosing compares two intravitreal dose levels given every 12 or ...